Pharmaceutical Industry News 26 September 2025

Biotech Breakthrough: Rani Therapeutics (RANI) Stock Skyrockets on $1B Deal – What Investors Need to Know

Rani Therapeutics (RANI) Stock Nearly Triples on $1B Chugai Deal – What Investors Should Know

Key Facts – October 18, 2025 RANI Stock Price Explodes on Deal News Rani Therapeutics’ stock price erupted on Friday, Oct. 17, 2025, after the company unveiled its game-changing pharma partnership and a significant financing boost. In pre-market trading, RANI

18 October 2025

Kenvue (KVUE) Stock Plummets to Record Low Amid Talc Lawsuit and Tylenol Scare

Stock Hits a 52-Week Low on Legal Woes Kenvue’s shares collapsed to an all-time low since their mid-2023 IPO, closing around $14 after Thursday’s 13.2% plunge stocktwits.com. The one-day drop – Kenvue’s worst on record – was triggered by headline

17 October 2025

Financial Analysis · Health News · Lawsuits · NYSE:KVUE · Pharmaceutical Industry · Stock Market

Protagonist Therapeutics (PTGX) Skyrockets on J&J Buyout Buzz Amid Clinical Breakthroughs

Recent News and Corporate Developments J&J Buyout Buzz: The biggest news propelling Protagonist’s stock is the report that Johnson & Johnson is in talks to acquire Protagonist reuters.com. On October 10, 2025, The Wall Street Journal broke the story (later confirmed by Reuters) that

10 October 2025

Biotech Stocks · Clinical Trials · Investment Opportunities · Mergers & Acquisitions · NASDAQ:PTGX · Pharmaceutical Industry

Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict

Pfizer’s Stock Surges: How Trump’s Pricing Deal and Big Drug Bets Sparked the Rally

Share Price & Recent Performance In early September 2025, Pfizer (NYSE:PFE) was trading in the mid–$20 range. After a relatively quiet first weeks of the month, the stock exploded higher at month-end. On Sept. 30, PFE closed at $25.48 after soaring

2 October 2025

Business Trends · Healthcare News · Investing · NYSE:PFE · Pharmaceutical Industry · Stock Market

Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict

Stock Price and Recent Performance Pfizer’s stock has struggled in 2025, hovering near multi-year lows. At ~$23.60 per share in late September, PFE has declined about 9% since January, underperforming the S&P 500 (which is up modestly) and lagging the

26 September 2025

Dividends · Investing · Market Analysis · Pharmaceutical Industry · Stock Market · Stocks

Pharmaceutical Industry News 26 September 2025 - 18 October 2025

Rani Therapeutics (RANI) Stock Nearly Triples on $1B Chugai Deal – What Investors Should Know

Kenvue (KVUE) Stock Plummets to Record Low Amid Talc Lawsuit and Tylenol Scare

Protagonist Therapeutics (PTGX) Skyrockets on J&J Buyout Buzz Amid Clinical Breakthroughs

Pfizer’s Stock Surges: How Trump’s Pricing Deal and Big Drug Bets Sparked the Rally

Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict